Scott L. Dax

1.4k total citations
50 papers, 1.1k citations indexed

About

Scott L. Dax is a scholar working on Molecular Biology, Organic Chemistry and Cellular and Molecular Neuroscience. According to data from OpenAlex, Scott L. Dax has authored 50 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 17 papers in Organic Chemistry and 11 papers in Cellular and Molecular Neuroscience. Recurrent topics in Scott L. Dax's work include Ion Channels and Receptors (10 papers), Neuropeptides and Animal Physiology (8 papers) and Pain Mechanisms and Treatments (7 papers). Scott L. Dax is often cited by papers focused on Ion Channels and Receptors (10 papers), Neuropeptides and Animal Physiology (8 papers) and Pain Mechanisms and Treatments (7 papers). Scott L. Dax collaborates with scholars based in United States, Switzerland and India. Scott L. Dax's co-authors include Mark A. Youngman, James J. McNally, Joseph P. Marino, Sui‐Po Zhang, Adrienne E. Dubin, Ellen E. Codd, Nadia Nasser, Mark E. McDonnell, Dennis J. Stone and Timothy W. Lovenberg and has published in prestigious journals such as The FASEB Journal, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Scott L. Dax

50 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Scott L. Dax United States 19 493 450 245 222 160 50 1.1k
Marianna Nalli Italy 21 238 0.5× 375 0.8× 158 0.6× 149 0.7× 107 0.7× 52 1.1k
Christopher Walpole Canada 17 209 0.4× 584 1.3× 477 1.9× 841 3.8× 553 3.5× 29 1.6k
Brian S. Brown United States 15 314 0.6× 222 0.5× 81 0.3× 268 1.2× 249 1.6× 21 818
Craig R. Schneider United States 16 181 0.4× 207 0.5× 173 0.7× 179 0.8× 110 0.7× 18 810
Larry V. Pearce United States 17 162 0.3× 359 0.8× 178 0.7× 671 3.0× 259 1.6× 45 1.0k
Gniewomir Latacz Poland 24 625 1.3× 771 1.7× 291 1.2× 57 0.3× 145 0.9× 128 1.7k
A. Rutledge United States 18 248 0.5× 493 1.1× 266 1.1× 72 0.3× 76 0.5× 32 959
Suat Tekin Türkiye 23 465 0.9× 300 0.7× 54 0.2× 35 0.2× 237 1.5× 98 1.3k
James Oluwagbamigbe Fajemiroye Brazil 18 204 0.4× 253 0.6× 165 0.7× 38 0.2× 100 0.6× 72 963
Siham M. El‐Shenawy Egypt 18 361 0.7× 250 0.6× 70 0.3× 12 0.1× 136 0.8× 42 1.2k

Countries citing papers authored by Scott L. Dax

Since Specialization
Citations

This map shows the geographic impact of Scott L. Dax's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott L. Dax with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott L. Dax more than expected).

Fields of papers citing papers by Scott L. Dax

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott L. Dax. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott L. Dax. The network helps show where Scott L. Dax may publish in the future.

Co-authorship network of co-authors of Scott L. Dax

This figure shows the co-authorship network connecting the top 25 collaborators of Scott L. Dax. A scholar is included among the top collaborators of Scott L. Dax based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott L. Dax. Scott L. Dax is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
McLeod, James F., et al.. (2014). GAL-021, a new intravenous BKCa-channel blocker, is well tolerated and stimulates ventilation in healthy volunteers. British Journal of Anaesthesia. 113(5). 875–883. 27 indexed citations
2.
Zhu, Bin, Mingde Xia, Donald Ludovici, et al.. (2013). Arylglycine derivatives as potent transient receptor potential melastatin 8 (TRPM8) antagonists. Bioorganic & Medicinal Chemistry Letters. 23(7). 2234–2237. 24 indexed citations
3.
Matthews, Jay M., Na Qin, Raymond W. Colburn, et al.. (2012). The design and synthesis of novel, phosphonate-containing transient receptor potential melastatin 8 (TRPM8) antagonists. Bioorganic & Medicinal Chemistry Letters. 22(8). 2922–2926. 28 indexed citations
4.
McNally, James J., Mark A. Youngman, Mark E. McDonnell, et al.. (2008). N-Pyridin-3-yl- and N-quinolin-3-yl-benzamides: Modulators of Human Vanilloid Receptor 1 (TRPV1). Bioorganic & Medicinal Chemistry Letters. 18(8). 2730–2734. 4 indexed citations
5.
Youngman, Mark A., James J. McNally, Mark E. McDonnell, et al.. (2007). Heteroaryl β-tetralin ureas as novel antagonists of human TRPV1. Bioorganic & Medicinal Chemistry Letters. 17(22). 6160–6163. 18 indexed citations
6.
Codd, E E, John R. Carson, Raymond W. Colburn, et al.. (2006). The Novel, Orally Active, Delta Opioid RWJ-394674 Is Biotransformed to the Potent Mu Opioid RWJ-413216. Journal of Pharmacology and Experimental Therapeutics. 318(3). 1273–1279. 14 indexed citations
7.
Carson, John R., Steven J. Coats, Ellen E. Codd, et al.. (2004). N , N -Dialkyl-4-[(8-azabicyclo[3.2.1]-oct-3-ylidene)phenylmethyl]benzamides, potent, selective δ opioid agonists. Bioorganic & Medicinal Chemistry Letters. 14(9). 2109–2112. 18 indexed citations
8.
Coats, Steven J., Mark J. Schulz, John R. Carson, et al.. (2004). Parallel methods for the preparation and SAR exploration of N-ethyl-4-[(8-alkyl-8-aza-bicyclo[3.2.1]oct-3-ylidene)-aryl-methyl]-benzamides, powerful mu and delta opioid agonists. Bioorganic & Medicinal Chemistry Letters. 14(22). 5493–5498. 20 indexed citations
9.
Youngman, Mark A., James J. McNally, Sui‐Po Zhang, et al.. (2004). N-Isoquinolin-5-yl-N′-aralkyl-urea and -amide antagonists of human vanilloid receptor 1. Bioorganic & Medicinal Chemistry Letters. 14(12). 3053–3056. 18 indexed citations
10.
Jablonowski, Jill A., Wenying Chai, Xiaobing Li, et al.. (2004). Novel non-peptidic neuropeptide Y Y 2 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 14(5). 1239–1242. 17 indexed citations
11.
Carson, John R., Steven J. Coats, Ellen E. Codd, et al.. (2004). N -Alkyl-4-[(8-azabicyclo[3.2.1]-oct-3-ylidene)phenylmethyl]benzamides, μ and δ opioid agonists: a μ address. Bioorganic & Medicinal Chemistry Letters. 14(9). 2113–2116. 6 indexed citations
12.
Youngman, Mark A., John R. Carson, Scott L. Dax, et al.. (2003). Synthesis and structure–Activity relationships of aroylpyrrole alkylamide bradykinin (B2) antagonists. Bioorganic & Medicinal Chemistry Letters. 13(7). 1341–1344. 4 indexed citations
13.
McDonnell, Mark E., et al.. (2003). 7-Hydroxynaphthalen-1-yl-urea and -amide antagonists of human vanilloid receptor 1. Bioorganic & Medicinal Chemistry Letters. 14(2). 531–534. 16 indexed citations
14.
Lee, Jung Eun, Charles H. Reynolds, Mark A. Youngman, et al.. (2003). Design and synthesis of novel pyrrolidine-containing bradykinin antagonists. Bioorganic & Medicinal Chemistry Letters. 13(11). 1879–1882. 11 indexed citations
15.
Luo, Chi, Brian C. Zanoni, Scott L. Dax, et al.. (2001). Aminopyrazoles with high affinity for the human neuropeptide Y5 receptor. Bioorganic & Medicinal Chemistry Letters. 11(17). 2283–2286. 27 indexed citations
16.
McNally, James J., Mark A. Youngman, Timothy W. Lovenberg, et al.. (2000). N-(Sulfonamido)alkyl[tetrahydro-1H-benzo[e]indol-2-yl]amines: potent antagonists of human neuropeptide Y Y5 receptor. Bioorganic & Medicinal Chemistry Letters. 10(3). 213–216. 17 indexed citations
17.
McNally, James J., Mark A. Youngman, Timothy W. Lovenberg, et al.. (2000). N-Acylated α-(3-pyridylmethyl)-β-aminotetralin antagonists of the human neuropeptide Y Y5 receptor. Bioorganic & Medicinal Chemistry Letters. 10(15). 1641–1643. 13 indexed citations
18.
Dax, Scott L., Norma Dunlap, N H Georgopapadakou, et al.. (1992). Dual-action penems and carbapenems. Journal of Medicinal Chemistry. 35(10). 1828–1839. 35 indexed citations
19.
Vedējs, Edwin & Scott L. Dax. (1989). Indoloquinones from azomethine ylides via the 4-oxazoline route. Tetrahedron Letters. 30(20). 2627–2630. 11 indexed citations
20.
Marino, Joseph P. & Scott L. Dax. (1987). Synthesis and rearrangements of ortho-selenonium phenoxides. Tetrahedron Letters. 28(35). 4007–4010. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marianna Nalli Breakdown of academic impact, for papers by Christopher Walpole Breakdown of academic impact, for papers by Brian S. Brown Breakdown of academic impact, for papers by Craig R. Schneider Breakdown of academic impact, for papers by Larry V. Pearce Breakdown of academic impact, for papers by Gniewomir Latacz Breakdown of academic impact, for papers by A. Rutledge Breakdown of academic impact, for papers by Suat Tekin Breakdown of academic impact, for papers by James Oluwagbamigbe Fajemiroye Breakdown of academic impact, for papers by Siham M. El‐Shenawy
Rankless by CCL
2026